Retinoic acid (RA), the major bioactive metabolite of retinol or vitamin A, induces a spectrum
of pleiotropic effects in cell growth and differentiation that are relevant for embryonic …

Acute promyelocytic leukemia (APL) is characterized by a number of features that underpin
the need for rapid and accurate diagnosis and demand a highly specific treatment approach …

To explore the genetic abnormalities that cooperate with AML1-ETO (AE) fusion gene to
cause acute myeloid leukemia (AML) with t (8; 21), we screened a number of candidate …

Most acute promyelocytic leukemia (APL) are caused by PML-RARA, a translocation-driven
fusion oncoprotein discovered three decades ago. Over the years, several other types of …

The therapeutic approach to the patient with acute myeloid leukemia (AML) currently
evolves toward new frontiers. This is particularly apparent from the entree of high-throughput …

The diagnosis of acute promyelocytic leukemia (APL) relies on the identification of PML::
RARA fusion. While the majority of APL cases harbor a typical t (15; 17)(q24; q21), atypical …

Abstract The t (15; 17)(q22; q21) translocation is tightly linked to the APL phenotype, and the
resultant PML-RAR fusion can be demonstrated in 98% of APL cases. Rare variant …

Acute promyelocytic leukemia (APL) accounts for 10–15% of newly diagnosed acute
myeloid leukemias (AML) and is typically caused by the fusion of promyelocytic leukemia …

It has been suggested that 1–2% of acute promyelocytic leukemia (APL) patients present
variant rearrangements of retinoic acid receptor alpha (RARα) fusion gene, with the …

The addition of arsenic trioxide (ATO) to frontline therapy of acute promyelocytic leukemia
(APL) has been shown to result in significant improvements in disease-free survival (DFS) …